GleamWall
中文EN

TPST Tempest Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1544227 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-12.6%
TTM EPS YoY67.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-1,797.6%
ROA-313.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets120.9%
Debt / equity—
Current ratio0.34x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.39x
Accruals ratio-189.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$12.61M$28.48M
SG&A expense$13.97M$13.55M
Operating income-$26.57M-$42.03M
Interest expense$207,000$1.32M
Income tax$0$0
Net income-$26.26M-$41.84M
EBITDA-$26.31M-$41.64M
EPS (basic)-6.33-19.50
EPS (diluted)-6.33-19.50
Weighted avg. shares (diluted)4.15M2.15M
Balance sheet
Cash & equivalents$7.71M$30.71M
Current assets$8.27M$31.47M
PP&E, net$605,000$886,000
Total assets$16.93M$41.49M
Current liabilities$3.31M$14.22M
Short-term debt$0$6.35M
Long-term debt—$0
Total debt—$6.35M
Total liabilities$10.26M$22.36M
Shareholders' equity$6.67M$19.13M
Net debt—-$24.36M
Shares outstanding4.93M3.38M
Cash flow statement
Operating cash flow-$26.82M-$33.03M
Capital expenditure$0$435,000
Free cash flow-$26.82M-$33.46M
Investing cash flow$0-$435,000
Financing cash flow$4.26M$24.50M
Depreciation & amortization$266,000$389,000
Stock-based compensation$3.12M$5.30M

Free plan shows the latest 2 periods; Pro shows all 15 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.